Little is planned in the laboratory. This brings up an important point: the value of technological or even drug-based innovations really only gets understood once they're in the health care system—and not necessarily funded as general funding, but partly funded as a research activity.
Related to all these topics is the fact that the health care system itself is part of what figures out what's going to work. The message that I was bringing forward was that we need to understand how to measure. That's the HTA piece. At the same time, we have to understand how these technologies impact the processes that are active in health care. The health care system is the place where we figure out that something has value. If we don't have the players there to enable that innovation, then we're really undercapitalizing on the opportunity.